The termination removes a potential overhang from future ATM sales but also signals the company may not need equity financing near-term or has secured alternative funding. Watch for any new financing arrangements or cash runway updates.
Price Chart
Executive Summary
Artelo Biosciences terminated its At-The-Market Offering Agreement with R.F. Lafferty, which had allowed up to $6.5M in common stock sales. Only $451,527 was raised via 50,858 shares before termination. The company's voluntary exit from this facility removes a potential equity dilution source but also eliminates a capital-raising option for the $5M market cap biotech.
Key Facts
- Terminated ATM agreement with R.F. Lafferty dated July 18, 2025
- Agreement allowed up to $6,500,000 in common stock sales
- Only $451,526.95 raised through 50,858 shares sold
- Termination effective May 18, 2026
Financial Impact
Undisclosed; no termination fees mentioned. The unused $6M capacity is now unavailable.
Risk Factors
- Company may need capital but lost a flexible funding source
- No replacement financing announced; potential future dilutive offering
- Micro-cap biotech with low liquidity and high cash burn risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001640334-26-000903 |
| Document: 0001640334-26-000903-index-headers.html | 0001640334-26-000903 |
| Document: 0001640334-26-000903-index.html | 0001640334-26-000903 |
| Document: 0001640334-26-000903.txt | 0001640334-26-000903 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $3.11 | awaiting T+60 | — | $2.20 (+29.26%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.20 (−41.33%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.20 (−67.79%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.20 (+109.52%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.20 (−98.20%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.20 (−50.68%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.20 (+61.76%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.20 (+50.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers